At the 43rd Annual J.P. Morgan Healthcare Conference (JPM Conference), which attracted the attention of global medical industry, Sungen Biomedical's innovative bi-specific antibody SGT003 was unveiled. The "Chinese Plan" of bioinnovative drugs was shown to the world, which received wide attentions from all participants.
Sungen's bispecific antibody platform has demonstrated excellent antibody performance, breaking through the limitation of existing treatments. Based on this platform, Sungen Biomedical has laid out a series of tumor treatment pipelines. At the JPM conference, after releasing the research progress of the world's first myocardial infarction emergency antibody drug SGC001, Sungen Biomedical once again released the progress data of anti-tumor core pipeline SGT003.
The bispecific antibody SGT003 targets immunosuppressed Tregs cells in the tumor microenvironment. Data from preclinical studies show that SGT003 significantly reduces the number of Tregs and TAMs. Under lower doses, SGT003 has more significant tumor inhibitory effects than anti-PD-1 and anti-CTLA-4 monoclonal antibody, and does not stimulate the release of TNF-α and other factors, which greatly improves the safety, showing excellent advantages in tumor treatment. In addition, anti-tumor immune memory can be obtained after SGT003 treatment, which effectively prevented tumor recurrence. SGT003 has the potential to become a more effective and safer first-line cornerstone drug as a new generation of tumor immunotherapy.
Sungen Biomedical is an innovation-driven Biomedical technology company. With its outstanding scientific research and innovative drug development capabilities, Sungen Biomedical has established a pipeline of original biomacromolecular drug products with great future potential, including the treatment of cardiovascular and cerebrovascular diseases, tumors, neurodegeneration and other diseases.
The JPM Conference is one of the largest and most informative top events in the global medical and health field, and is a vane for the development and investment in the global medical and health field. Sungen Biomedical's core bispecific antibody product SGT003 made an exciting appearance at the JPM conference, not only demonstrating its technological innovation capability on the bispecific antibody platform, but also marking Sungen Biomedical's breakthrough progress in the field of tumor immunotherapy. Sungen Biomedical will accelerate the global commercialization of SGT003 and strive to provide safer and more effective therapeutic options for cancer patients around the world.
Updated: Mar 20, 2025
